Olema Pharmaceuticals, Inc. announces FDA clearance for OP-3136, aimed at targeting breast cancer treatment.
Dec 09, 2024
San FranciscoBiotechnologyHealthcareHealth CareTherapeuticsPharmaceutical
Product Description
Olema Pharmaceuticals, Inc. announced that the FDA has cleared their Investigational New Drug application for OP-3136, a potent KAT6 inhibitor, allowing them to proceed to clinical trials. The Phase 1 clinical trial is expected to start early next year.
Company Information
Company
Olema Pharmaceuticals, Inc.
Location
665 3RD STREET SUITE 250
San Francisco, California, United States
About
Olema Pharmaceuticals is a preclinical biotechnology company.
Fundz sees it the moment Olema Pharmaceuticals, Inc. ships something new, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
San FranciscoBiotechnologyHealthcareHealth CareTherapeuticsPharmaceutical